250 related articles for article (PubMed ID: 24778996)
1. Immunological derangement in hypocellular myelodysplastic syndromes.
Serio B; Risitano A; Giudice V; Montuori N; Selleri C
Transl Med UniSa; 2014 Jan; 8():31-42. PubMed ID: 24778996
[TBL] [Abstract][Full Text] [Related]
2. Immunologic aspects of hypoplastic myelodysplastic syndrome.
Calado RT
Semin Oncol; 2011 Oct; 38(5):667-72. PubMed ID: 21943673
[TBL] [Abstract][Full Text] [Related]
3. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies.
Selleri C; Maciejewski JP; Catalano L; Ricci P; Andretta C; Luciano L; Rotoli B
Cancer; 2002 Nov; 95(9):1911-22. PubMed ID: 12404285
[TBL] [Abstract][Full Text] [Related]
4. Special Education: Aplastic Anemia.
Teramura M; Mizoguchi H
Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986
[TBL] [Abstract][Full Text] [Related]
5. Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?
Fattizzo B; Serpenti F; Barcellini W; Caprioli C
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401595
[No Abstract] [Full Text] [Related]
6. Hypoplastic myelodysplastic syndrome and acquired aplastic anemia: Immune‑mediated bone marrow failure syndromes (Review).
Votavova H; Belickova M
Int J Oncol; 2022 Jan; 60(1):. PubMed ID: 34958107
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
[TBL] [Abstract][Full Text] [Related]
8. Expression of interferon-gamma and tumor necrosis factor-alpha in bone marrow T cells and their levels in bone marrow plasma in patients with aplastic anemia.
Dubey S; Shukla P; Nityanand S
Ann Hematol; 2005 Sep; 84(9):572-7. PubMed ID: 15815907
[TBL] [Abstract][Full Text] [Related]
9. [Abnormal polarization of T lymphocyte induces negative hematopoietic regulation in myelodysplastic syndromes].
Wu LY; Li X; Chang CK; Ying SX; Pu Q
Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):549-54. PubMed ID: 18078133
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
Barrett J; Saunthararajah Y; Molldrem J
Semin Hematol; 2000 Jan; 37(1):15-29. PubMed ID: 10676908
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis-induced aplastic crisis and atypical lymphocyte expansion in advanced myelodysplastic syndrome: A case report and review of literature.
Sun XY; Yang XD; Xu J; Xiu NN; Ju B; Zhao XC
World J Clin Cases; 2023 Jul; 11(19):4713-4722. PubMed ID: 37469724
[TBL] [Abstract][Full Text] [Related]
12. CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS.
Cha CH; Park CJ; Chi HS; Seo EJ; Jang S; Cho YU; Lee KH; Lee JH; Lee JH; Im HJ; Seo JJ
Ann Lab Med; 2014 Nov; 34(6):426-32. PubMed ID: 25368817
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia.
Maciejewski JP; Selleri C; Sato T; Anderson S; Young NS
Br J Haematol; 1995 Sep; 91(1):245-52. PubMed ID: 7577642
[TBL] [Abstract][Full Text] [Related]
14. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome.
Durrani J; Maciejewski JP
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):97-104. PubMed ID: 31808900
[TBL] [Abstract][Full Text] [Related]
16. Immunologic effects on the haematopoietic stem cell in marrow failure.
Patel BA; Giudice V; Young NS
Best Pract Res Clin Haematol; 2021 Jun; 34(2):101276. PubMed ID: 34404528
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes.
Matsui WH; Brodsky RA; Smith BD; Borowitz MJ; Jones RJ
Leukemia; 2006 Mar; 20(3):458-62. PubMed ID: 16437138
[TBL] [Abstract][Full Text] [Related]
18. Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
Shao LL; Zhang L; Hou Y; Yu S; Liu XG; Huang XY; Sun YX; Tian T; He N; Ma DX; Peng J; Hou M
PLoS One; 2012; 7(12):e51339. PubMed ID: 23236476
[TBL] [Abstract][Full Text] [Related]
19. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.
Afable MG; Wlodarski M; Makishima H; Shaik M; Sekeres MA; Tiu RV; Kalaycio M; O'Keefe CL; Maciejewski JP
Blood; 2011 Jun; 117(25):6876-84. PubMed ID: 21527527
[TBL] [Abstract][Full Text] [Related]
20. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.
Zang DY; Goodwin RG; Loken MR; Bryant E; Deeg HJ
Blood; 2001 Nov; 98(10):3058-65. PubMed ID: 11698291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
